Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh
· Delayed Price · Currency is BDT 209.80
+2.50 (1.21%)
At close: Mar 9, 2026
DSE:SQURPHARMA Ratios and Metrics
Market cap in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Market Capitalization | 185,977 | 185,180 | 186,953 | 185,977 | 192,094 | 191,030 | Upgrade
|
| Market Cap Growth | -3.18% | -0.95% | 0.52% | -3.18% | 0.56% | 31.17% | Upgrade
|
| Enterprise Value | 116,024 | 126,115 | 130,781 | 132,967 | 141,464 | 147,209 | Upgrade
|
| Last Close Price | 209.80 | 197.14 | 189.15 | 178.84 | 176.04 | 170.40 | Upgrade
|
| PE Ratio | 7.17 | 7.73 | 8.93 | 9.80 | 10.58 | 11.98 | Upgrade
|
| Forward PE | 6.51 | 7.25 | 8.30 | 9.10 | 9.93 | 10.40 | Upgrade
|
| PS Ratio | 2.27 | 2.43 | 2.67 | 3.06 | 3.34 | 3.77 | Upgrade
|
| PB Ratio | 1.29 | 1.32 | 1.49 | 1.61 | 1.83 | 2.10 | Upgrade
|
| P/TBV Ratio | 1.29 | 1.32 | 1.49 | 1.61 | 1.83 | 2.10 | Upgrade
|
| P/FCF Ratio | 12.37 | 16.65 | 13.03 | 32.71 | 28.71 | 26.61 | Upgrade
|
| P/OCF Ratio | 8.60 | 10.70 | 10.09 | 21.76 | 14.92 | 17.40 | Upgrade
|
| PEG Ratio | - | 0.68 | 0.68 | 0.70 | 0.71 | 0.69 | Upgrade
|
| EV/Sales Ratio | 1.42 | 1.65 | 1.87 | 2.19 | 2.46 | 2.90 | Upgrade
|
| EV/EBITDA Ratio | 4.31 | 5.84 | 6.45 | 7.00 | 7.57 | 8.58 | Upgrade
|
| EV/EBIT Ratio | 4.69 | 6.50 | 7.28 | 7.97 | 8.39 | 9.64 | Upgrade
|
| EV/FCF Ratio | 7.72 | 11.34 | 9.12 | 23.39 | 21.14 | 20.51 | Upgrade
|
| Debt / Equity Ratio | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 | Upgrade
|
| Debt / EBITDA Ratio | 0.02 | 0.04 | 0.07 | 0.10 | 0.10 | 0.01 | Upgrade
|
| Debt / FCF Ratio | 0.03 | 0.07 | 0.10 | 0.35 | 0.29 | 0.01 | Upgrade
|
| Net Debt / Equity Ratio | -0.49 | -0.46 | -0.48 | -0.46 | -0.49 | -0.53 | Upgrade
|
| Net Debt / EBITDA Ratio | -2.92 | -2.99 | -2.95 | -2.77 | -2.75 | -2.79 | Upgrade
|
| Net Debt / FCF Ratio | -4.65 | -5.81 | -4.17 | -9.27 | -7.68 | -6.67 | Upgrade
|
| Asset Turnover | 0.53 | 0.55 | 0.55 | 0.52 | 0.56 | 0.57 | Upgrade
|
| Inventory Turnover | 3.08 | 3.15 | 3.03 | 3.18 | 3.72 | 3.94 | Upgrade
|
| Quick Ratio | 3.86 | 10.22 | 10.70 | 13.29 | 14.30 | 14.56 | Upgrade
|
| Current Ratio | 4.73 | 12.80 | 13.48 | 16.67 | 17.03 | 17.33 | Upgrade
|
| Return on Equity (ROE) | 19.01% | 18.03% | 17.36% | 17.22% | 18.52% | 18.96% | Upgrade
|
| Return on Assets (ROA) | 8.84% | 8.67% | 8.83% | 8.93% | 10.17% | 10.77% | Upgrade
|
| Return on Invested Capital (ROIC) | 20.41% | 20.02% | 20.86% | 21.41% | 25.42% | 26.37% | Upgrade
|
| Return on Capital Employed (ROCE) | 15.00% | 13.80% | 14.10% | 14.20% | 15.60% | 16.50% | Upgrade
|
| Earnings Yield | 13.95% | 12.94% | 11.19% | 10.21% | 9.45% | 8.35% | Upgrade
|
| FCF Yield | 8.08% | 6.01% | 7.67% | 3.06% | 3.48% | 3.76% | Upgrade
|
| Dividend Yield | 5.79% | 6.09% | 5.82% | 5.87% | 5.68% | 3.52% | Upgrade
|
| Payout Ratio | 37.44% | 40.51% | 44.32% | 46.38% | 29.20% | 24.60% | Upgrade
|
| Total Shareholder Return | 5.79% | 6.09% | 5.82% | 5.87% | 5.68% | 3.52% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.